Skip to main content

Table 1 Baseline and microbiological characteristics of patients

From: A phase 1 trial of nebulised heparin in acute lung injury

Variable Dose Combined n (%)
  50,000 U/day 100,000 U/day 200,000 U/day 400,000 U/day  
Number of patients 4 4 4 4 16
Age (years) 57.7 ± 17.3 61.3 ± 14.2 54.3 ± 17.6 60.0 ± 13.0 58.3 ± 14.3
Male 2 1 4 1 8 (50)
Acute Physiological and Chronic Health Evaluation II score 22.3 ± 6.0 21.8 ± 8.7 18.3 ± 10 20.0 ± 3.4 20.6 ± 7.0
Subcutaneous heparin 4 3 4 3 14 (88)
Arterial to inspired oxygen ratio (mmHg) 159 ± 37 143 ± 48 207 ± 79 226 ± 75 183 ± 66
Lung compliance (ml/cmH2O) 30 ± 7 19 ± 5 37 ± 21 22 ± 14 26 ± 14
Alveolar dead space fraction 0.15 ± 0.04 0.3 ± 0.10 0.17 ± 0.07 0.24 ± 0.1 0.23 ± 0.1
Creatinine (μmol/l) 80 ± 45 56 ± 14 130 ± 154 97 ± 45 91 ± 80
Activated partial thromboplastin time (s) 38 ± 7 37 ± 6 44 ± 7 47 ± 20 41 ± 11
Thrombin clotting time (s) 17 ± 2 21 ± 3 20 ± 10 19 ± 3 19 ± 5
Acute lung injury cause      
   Pneumonia 3 3 2 2 10 (63)
   Sepsis 0 0 1 1 2 (13)
   Pancreatitis 0 1 0 1 2 (13)
   Empyema 1 0 1 0 2 (13)
   Aspiration 0 0 0 0 0
Surgical admission 3 0 1 2 6 (38)
Microbiology      
   Gram-negative 1 0 2 1 4 (25)
   Gram-positive 1 2 1 0 4 (25)
   Other 0 1 0 2 3 (19)
   No pathogen detected 2 1 1 1 5 (31)
Blood culture-positive 0 0 1 1 2 (12)